CME Information
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal and choroidal vascular diseases.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the angiopoietin/Tie2 pathway as a key regulator of vascular development and maintenance, homeostasis, and inflammation in retinal and choroidal vascular diseases.
- Summarize safety and efficacy data for injectable therapies that act on the angiopoietin/Tie2 pathway and may improve visual outcomes in patients with retinal and choroidal vascular diseases.
Activity Chair
Karl G. Csaky, MD, PhD
T. Boone Pickens Director
Molecular Ophthalmology Laboratory
Director, Clinical Center of Innovation for Age-Related Macular Degeneration
Chief Executive and Medical Officer
Retina Foundation of the Southwest
Dallas, TX
Faculty
Anat Loewenstein, MD
Professor & Director, Ophthalmology Division
Tel-Aviv Medical Center
Associate Dean of Medicine
Tel-Aviv University
Tel Aviv, Israel
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Medical Writer
Linda Geisler
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, September 30, 2022, to September 29, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The articles in this monograph were composed by a medical writer, Linda Geisler, based on the presentations of Drs. Csaky and Loewenstein during an expert panel held on May 12, 2022. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Activity Chair and Faculty report the following relevant financial relationship(s)
Karl G. Csaky, MD, PhD
Consultant: AbbVie/Allergan, Adverum, Annexon, Cognition Therapeutics, Genentech/Roche, Gyroscope, J&J Vision, Merck, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Retrotope, Ribomic
Speaker Contracted by Ineligible Company: Genentech
Independent Research Contractor: Annexon, Boehringer Ingelheim, Genentech/Roche, Gyroscope, NGM Biopharmaceuticals
Anat Loewenstein, MD
Consultant: Allergan, Bayer, Notal Vision, Novartis, Roche
Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Medical Reviewer reports the following relevant financial relationship(s)
Linda Geisler
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com